ClinicalTrials.gg
CompletedNCT04373512Updated Nov 3, 2026Results posted

Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury

A Phase 2 interventional study of Culturelle 10 Billion CFU Capsule (2 doses) and Culturelle 10 Billion CFU Capsule (4 doses) in Spinal Cord Injuries and Neurogenic Bladder, sponsored by Medstar Health Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Medstar Health Research Institute · Phase 2, Interventional, and Prevention

How we know

Updated Nov 3, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 968 studies in Spinal Cord Injuries with a site in United States — 249 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Enrollment
39th of 836
182 · median 24
Started
2020
with 46 others
Phase 2
77 of 968
6 open now
Registered
557th of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 39th largest by enrollment of the 836 interventional ones that give a count, is one of 47 that started in 2020, is one of 77 in phase 2, and was the 557th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

249 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.

Read the detailed description

Urinary tract infection (UTI) is the most common outpatient infection world-wide, and for people with spinal cord injury (SCI) and neurogenic bladder (NB), it is the most common infection, secondary condition, cause for emergency room visits, and infectious cause of hospitalization. Despite its prevalence, attempts to ameliorate UTI among people with SCI are stymied by long-standing diagnostic challenges which arise from evidence gaps around "gold standard" diagnostic tests (urinalysis and urine culture) that have lower sensitivity and specificity for UTI in this population. A high prevalence of chronic inflammation leading to persistence of white blood cells (WBC) in the urine confounds the utility of WBC count, pyuria, and leukocyte esterase as biomarkers for UTI; nitrites in urine indicate the presence of only specific (but not all) organisms, many of which are present to a greater extent in the urine of people with SCI; and people with SCI have a high prevalence of asymptomatic bacteriuria. These physiologic changes render the gold standard diagnostic tests less useful for identifying UTI in persons with SCI.

SPECIFIC AIM 1

2 urine samples (sampling at least 2 weeks apart) for urinalysis, urine culture, uNGAL, and NGS (16S rRNA and shotgun) under the same conditions. In addition to completing the USQNB-IC prior to urine collection, participants will complete the USQNB-IC 3 days after urine collection

SPECIFIC AIM 2 Intravesical LGG dose (group: high or low) will be obtained, USQNB-IC, urine collection for urinalysis, culture, NGAL and next generation sequencing as described above. And patient satisfaction questions.

03

Conditions studied

  • Spinal Cord Injuries
  • Neurogenic Bladder

Keywords

  • Intermittent Catheter
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SCI at least 1-year duration;
  • Neurogenic bladder;
  • Utilizing intermittent catheterization for bladder management;
  • Women must be premenopausal and not currently menstruating;
  • Community dwelling

Exclusion criteria

Exclusion Criteria:

  • Use of prophylactic antibiotics;
  • Instillation of intravesical antimicrobials to prevent UTI;
  • Psychologic or psychiatric conditions influencing the ability to follow instructions;
  • Use of oral or IV antibiotics within the past 2 weeks;
  • Sexual activity within the previous 72 hours;
  • Participation in another study with which results could be confounded.
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Low Dosage Group

    For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.

    Drug: Culturelle 10 Billion CFU Capsule (2 doses)

  • Experimental
    High Dosage Group

    For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.

    Drug: Culturelle 10 Billion CFU Capsule (4 doses)

Interventions

  • DrugCulturelle 10 Billion CFU Capsule (2 doses)

    For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules

    Also known as: Lactobacillus RhamnosusGG

  • DrugCulturelle 10 Billion CFU Capsule (4 doses)

    For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules

    Also known as: Lactobacillus RhamnosusGG

06

What researchers measure

Primary outcomes

  1. Number of Participants With Successful Reduction of Urinary Symptoms

    20% reduction in urinary symptoms within 48 hours of completion of intervention

    Time frame: Participants (low and high group) fill out the USQNB-IC at the onset of their symptoms, and 48 hours after the last dose. Definition of "success" is 20% reduction in number of endorsed symptoms between the first and final USQNB-IC.

Secondary outcomes

  1. Leukocyte Esterase

    urinary leukocyte esterase level (ordinal count levels)

    Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 36 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.

  2. Change in Cultivable Bacteria Pre and Post LGG Instillations

    Standard urine culture (SUC) results based on quantity (colony forming units) and identified organism. (number of organisms cultivated/identified; yes/no if any were cultivated at or greater than 10\^5)

    Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.

  3. Change in Urine Nitrite Pre and Post LGG Instillations

    Standard urine analysis. Urine derived nitrites (positive or negative)

    Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.

  4. Change in Urine White Blood Cell Count Pre and Post LGG Instillations

    urine derived white blood cells per high powered field (ordinal count levels)

    Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.

  5. Change in uNGAL Pre and Post LGG Instillations

    urinary neutrophil gelatinase-associated lipocalin in µg/L (continuous)

    Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.

07

Results

Posted Nov 3, 2026

Participant flow

Participants were recruited nationwide

Participant flow — Overall Study
MilestoneLow Dosage GroupHigh Dosage Group
Started8988
Completed6158
Not completed2830

Outcome measures

PrimaryNumber of Participants With Successful Reduction of Urinary Symptoms

20% reduction in urinary symptoms within 48 hours of completion of intervention

Time frame:
Participants (low and high group) fill out the USQNB-IC at the onset of their symptoms, and 48 hours after the last dose. Definition of "success" is 20% reduction in number of endorsed symptoms between the first and final USQNB-IC.
Reported as:
Count of participants · Participants
Number of Participants With Successful Reduction of Urinary Symptoms
ParticipantsLow Dosage GroupHigh Dosage Group
Number of Participants With Successful Reduction of Urinary Symptoms3028
SecondaryLeukocyte Esterase

urinary leukocyte esterase level (ordinal count levels)

Time frame:
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 36 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Reported as:
Number · participants
Leukocyte Esterase
participantsLow Dosage GroupHigh Dosage Group
Unchanged LE1213
Worsened LE21
Improved LE01
SecondaryChange in Cultivable Bacteria Pre and Post LGG Instillations

Standard urine culture (SUC) results based on quantity (colony forming units) and identified organism. (number of organisms cultivated/identified; yes/no if any were cultivated at or greater than 10\^5)

Time frame:
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Reported as:
Mean · 10^5 colony forming units
Change in Cultivable Bacteria Pre and Post LGG Instillations
10^5 colony forming unitsLow Dosage GroupHigh Dosage Group
Change in Cultivable Bacteria Pre and Post LGG Instillations.1429 ± .53452-.0769 ± .95407
SecondaryChange in Urine Nitrite Pre and Post LGG Instillations

Standard urine analysis. Urine derived nitrites (positive or negative)

Time frame:
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Reported as:
Number · participants
Change in Urine Nitrite Pre and Post LGG Instillations
participantsLow Dosage GroupHigh Dosage Group
Unchanged Nitrite1111
Improved Nitrite11
Worsened Nitrite23
SecondaryChange in Urine White Blood Cell Count Pre and Post LGG Instillations

urine derived white blood cells per high powered field (ordinal count levels)

Time frame:
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Reported as:
Count of participants · Participants
Change in Urine White Blood Cell Count Pre and Post LGG Instillations
ParticipantsLow Dosage GroupHigh Dosage Group
Unchanged WBC1011
Worsened (pyuria developed)44
SecondaryChange in uNGAL Pre and Post LGG Instillations

urinary neutrophil gelatinase-associated lipocalin in µg/L (continuous)

Time frame:
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Reported as:
Mean · µg/L value
Change in uNGAL Pre and Post LGG Instillations
µg/L valueLow Dosage GroupHigh Dosage Group
Change in uNGAL Pre and Post LGG Instillations143.9484 ± 466.5451410.3927 ± 117.07663

Adverse events

Collected over 4 years, 7 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dosage Group1/89 (1.1%)5/89 (5.6%)9/89 (10.1%)
High Dosage Group2/88 (2.3%)10/88 (11.4%)12/88 (13.6%)
Most frequent serious events
Most frequent serious events
EventLow Dosage GroupHigh Dosage Group
UTIRenal and urinary disorders3/893/88
UTI and COVIDRenal and urinary disorders0/891/88
Bilaterial Lower Extremity amputationSurgical and medical procedures0/891/88
CellulitisSkin and subcutaneous tissue disorders0/891/88
Septic shockRenal and urinary disorders0/891/88
Blood in catheterRenal and urinary disorders0/891/88
Prolapsed ostomySurgical and medical procedures0/891/88
DeathGeneral disorders0/891/88
Food infectionInfections and infestations1/890/88
Back PainGeneral disorders1/890/88
Most frequent other events
Most frequent other events
EventLow Dosage GroupHigh Dosage Group
Increase in urinary symptomsRenal and urinary disorders0/897/88
UTIRenal and urinary disorders5/893/88
Rash on handGeneral disorders0/891/88
Catheter tip syring not fitting the catheterRenal and urinary disorders0/891/88
AnxietyPsychiatric disorders1/890/88
HeadacheGeneral disorders1/890/88
burning while instillingRenal and urinary disorders1/890/88
Blood coming out around catheterInfections and infestations1/890/88
Back painGeneral disorders1/890/88

Baseline characteristics

Analyze results low dosage group compared to high dosage group. Both groups consists of individuals with neurogenic lower urinary tract dysfunction (spinal cord injury, spina bifida, multiple sclerosis), using intermittent catheterization for bladder management.

Age, Continuous
Age, Continuous(years)Low Dosage GroupHigh Dosage GroupTotal
Mean50 (22 to 75)47 (18 to 73)49 (18 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Low Dosage GroupHigh Dosage GroupTotal
Female374380
Male524597
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low Dosage GroupHigh Dosage GroupTotal
Hispanic or Latino628
Not Hispanic or Latino8386169
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dosage GroupHigh Dosage GroupTotal
American Indian or Alaska Native011
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American191332
White6669135
More than one race235
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Low Dosage GroupHigh Dosage GroupTotal
United States8988177
08

Study locations

1 site
  • MedStar National Rehabilitation Hospital
    Washington D.C., District of Columbia 20010, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2025, 56 months.

Results were first posted in Nov 2026, 1 year 8 months after primary completion.

Of 44 non-industry phase 2 interventional studies under Spinal Cord Injuries, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 64. This study's 56 months is above that.

Counting every sponsor, half of 49 studies reached it within 46 months; a quarter within 28 and three quarters within 64.

Start moved once since we started tracking on Sep 25, 2026: May 2020 → Jun 2020, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2019
First posted
May 4, 2020
StartActual
Jun 1, 2020was May 2020
Primary completionActual
Feb 14, 2025
CompletionActual
Feb 14, 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Sites
1 site added, 1 site removed
Show site
  • MedStar National Rehabilitation Hospital · Washington D.C., United States
Show 1 removed
  • MedStar National Rehabilitation Hospital · Washington, United States
Nov 3, 2026
Start date
May 20, 2020→Jun 1, 2020
Nov 3, 2026
Primary outcomes
1 added, 29 removed, 2 more
What changed in the outcomes
  • AddedNumber of Participants With Successful Reduction of Urinary SymptomsTime frame: Participants (low and high group) fill out the USQNB-IC at the onset of their symptoms, and 48 hours after the last dose. Definition of "success" is 20% reduction in number of endorsed symptoms between the first and final USQNB-IC.
  • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day of urine collection
  • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day 1 post urine collection
  • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day 2 post urine collection
  • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day 3 post urine collection
  • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA2) Weekly up to 29 months
  • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA2) day 1 of intervention
  • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA2) 24-48 hours after intervention completion
  • RemovedChange in Urine white blood cell countTime frame: (SA1) day 1 post urine collection
  • RemovedChange in Urine white blood cell countTime frame: (SA1) day 14 post urine collection
  • RemovedChange in Urine white blood cell countTime frame: (SA 2) day 1 of intervention
  • RemovedChange in Urine white blood cell countTime frame: (SA 2) 24-48 hours after intervention completion
  • RemovedChange in Urine NitriteTime frame: (SA1)day 1 post urine collection
  • RemovedChange in Urine NitriteTime frame: (SA1)day 14 post urine collection
  • RemovedChange in Urine NitriteTime frame: (SA 2) day 1 of intervention
  • RemovedChange in Urine NitriteTime frame: (SA 2) 24-48 hours after intervention completion
  • RemovedChange in Urine NGALTime frame: (SA1)day 1 post urine collection
  • RemovedChange in Urine NGALTime frame: (SA1)day 14 post urine collection
  • RemovedChange in Urine NGALTime frame: (SA 2) day 1 of intervention
  • RemovedChange in Urine NGALTime frame: (SA 2) 24-48 hours after intervention completion
  • RemovedChange in Cultivable BacteriaTime frame: (SA1)day 1 post urine collection
  • RemovedChange in Cultivable BacteriaTime frame: (SA1)day 14 post urine collection
  • RemovedChange in Cultivable BacteriaTime frame: (SA 2) day 1 of intervention
  • RemovedChange in Cultivable BacteriaTime frame: (SA 2) 24-48 hours after intervention completion
  • RemovedChange in Urine microbiome compositionTime frame: (SA1)day 1 post urine collection
  • RemovedChange in Urine microbiome compositionTime frame: (SA1)day 14 post urine collection
  • RemovedChange in Urine microbiome compositionTime frame: (SA 2) day 1 of intervention
  • RemovedChange in Urine microbiome compositionTime frame: (SA 2) 24-48 hours after intervention completion
  • RemovedInternational SCI Lower Urinary Tract Function Basic Data SetTime frame: Day 1
  • RemovedInternational SCI Core Data SetTime frame: Day 1
  • …and 2 more, on the record history on ClinicalTrials.gov ↗
Nov 3, 2026
Secondary outcomes
5 added
What changed in the outcomes
  • AddedLeukocyte EsteraseTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 36 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
  • AddedChange in Cultivable Bacteria Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
  • AddedChange in Urine Nitrite Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
  • AddedChange in Urine White Blood Cell Count Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
  • AddedChange in uNGAL Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Nov 3, 2026
Sponsor
Collaborators added: Congressionally Directed Medical Research Programs
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • MedStar National Rehabilitation Hospital · Washington D.C., United States
    Show 1 removed
    • MedStar National Rehabilitation Hospital · Washington, United States
    Start date May 20, 2020→Jun 1, 2020
    Primary outcomes 1 added, 29 removed, 2 more
    What changed in the outcomes
    • AddedNumber of Participants With Successful Reduction of Urinary SymptomsTime frame: Participants (low and high group) fill out the USQNB-IC at the onset of their symptoms, and 48 hours after the last dose. Definition of "success" is 20% reduction in number of endorsed symptoms between the first and final USQNB-IC.
    • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day of urine collection
    • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day 1 post urine collection
    • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day 2 post urine collection
    • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA1) day 3 post urine collection
    • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA2) Weekly up to 29 months
    • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA2) day 1 of intervention
    • RemovedUrinary Symptom Questionnaire for Neurogenic Bladder- Intermittent catheterTime frame: (SA2) 24-48 hours after intervention completion
    • RemovedChange in Urine white blood cell countTime frame: (SA1) day 1 post urine collection
    • RemovedChange in Urine white blood cell countTime frame: (SA1) day 14 post urine collection
    • RemovedChange in Urine white blood cell countTime frame: (SA 2) day 1 of intervention
    • RemovedChange in Urine white blood cell countTime frame: (SA 2) 24-48 hours after intervention completion
    • RemovedChange in Urine NitriteTime frame: (SA1)day 1 post urine collection
    • RemovedChange in Urine NitriteTime frame: (SA1)day 14 post urine collection
    • RemovedChange in Urine NitriteTime frame: (SA 2) day 1 of intervention
    • RemovedChange in Urine NitriteTime frame: (SA 2) 24-48 hours after intervention completion
    • RemovedChange in Urine NGALTime frame: (SA1)day 1 post urine collection
    • RemovedChange in Urine NGALTime frame: (SA1)day 14 post urine collection
    • RemovedChange in Urine NGALTime frame: (SA 2) day 1 of intervention
    • RemovedChange in Urine NGALTime frame: (SA 2) 24-48 hours after intervention completion
    • RemovedChange in Cultivable BacteriaTime frame: (SA1)day 1 post urine collection
    • RemovedChange in Cultivable BacteriaTime frame: (SA1)day 14 post urine collection
    • RemovedChange in Cultivable BacteriaTime frame: (SA 2) day 1 of intervention
    • RemovedChange in Cultivable BacteriaTime frame: (SA 2) 24-48 hours after intervention completion
    • RemovedChange in Urine microbiome compositionTime frame: (SA1)day 1 post urine collection
    • RemovedChange in Urine microbiome compositionTime frame: (SA1)day 14 post urine collection
    • RemovedChange in Urine microbiome compositionTime frame: (SA 2) day 1 of intervention
    • RemovedChange in Urine microbiome compositionTime frame: (SA 2) 24-48 hours after intervention completion
    • RemovedInternational SCI Lower Urinary Tract Function Basic Data SetTime frame: Day 1
    • RemovedInternational SCI Core Data SetTime frame: Day 1
    • …and 2 more, on the record history on ClinicalTrials.gov ↗
    Secondary outcomes 5 added
    What changed in the outcomes
    • AddedLeukocyte EsteraseTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 36 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
    • AddedChange in Cultivable Bacteria Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
    • AddedChange in Urine Nitrite Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
    • AddedChange in Urine White Blood Cell Count Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
    • AddedChange in uNGAL Pre and Post LGG InstillationsTime frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
    Sponsor Collaborators added: Congressionally Directed Medical Research Programs
    + 2 other changes: identifiers and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04373512
Collaborators
Children's National Research Institute, Congressionally Directed Medical Research Programs
Responsible party
Sponsor
First posted
May 4, 2020
Start date
Jun 1, 2020
Primary completion
Feb 14, 2025
Completion
Feb 14, 2025
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Suzanne Groah, MD, MSPH
principal investigator · MedStar National Rehabilitation Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion